Literature DB >> 20182843

Diagnostic performance of fluorodeoxyglucose positron emission tomography/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography/computed tomography.

Kazuya Nakajo1, Mitsuaki Tatsumi, Atsuo Inoue, Kayako Isohashi, Ichiro Higuchi, Hiroki Kato, Masao Imaizumi, Takayuki Enomoto, Eku Shimosegawa, Tadashi Kimura, Jun Hatazawa.   

Abstract

PURPOSE: We compared the diagnostic accuracy of fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and PET/magnetic resonance imaging (MRI) fusion images for gynecological malignancies.
MATERIALS AND METHODS: A total of 31 patients with gynecological malignancies were enrolled. FDG-PET images were fused to CT, T1- and T2-weighted images (T1WI, T2WI). PET-MRI fusion was performed semiautomatically. We performed three types of evaluation to demonstrate the usefulness of PET/MRI fusion images in comparison with that of inline PET/CT as follows: depiction of the uterus and the ovarian lesions on CT or MRI mapping images (first evaluation); additional information for lesion localization with PET and mapping images (second evaluation); and the image quality of fusion on interpretation (third evaluation).
RESULTS: For the first evaluation, the score for T2WI (4.68 +/- 0.65) was significantly higher than that for CT (3.54 +/- 1.02) or T1WI (3.71 +/- 0.97) (P < 0.01). For the second evaluation, the scores for the localization of FDG accumulation showing that T2WI (2.74 +/- 0.57) provided significantly more additional information for the identification of anatomical sites of FDG accumulation than did CT (2.06 +/- 0.68) or T1WI (2.23 +/- 0.61) (P < 0.01). For the third evaluation, the three-point rating scale for the patient group as a whole demonstrated that PET/T2WI (2.72 +/- 0.54) localized the lesion significantly more convincingly than PET/CT (2.23 +/- 0.50) or PET/T1WI (2.29 +/- 0.53) (P < 0.01).
CONCLUSION: PET/T2WI fusion images are superior for the detection and localization of gynecological malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182843     DOI: 10.1007/s11604-009-0387-3

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  21 in total

Review 1.  PET/CT: form and function.

Authors:  Todd M Blodgett; Carolyn C Meltzer; David W Townsend
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

2.  Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients.

Authors:  Seok-Ki Kim; Hyuck Jae Choi; Sang-Yoon Park; Ho-Young Lee; Sang-Soo Seo; Chong Woo Yoo; Dae Chul Jung; Sokbom Kang; Kyung-Sik Cho
Journal:  Eur J Cancer       Date:  2009-05-04       Impact factor: 9.162

3.  Combined PET/CT Imaging in Oncology. Impact on Patient Management.

Authors:  P G. Kluetz; C C. Meltzer; V L. Villemagne; P E. Kinahan; S Chander; M A. Martinelli; D W. Townsend
Journal:  Clin Positron Imaging       Date:  2000-11

4.  Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.

Authors:  Osama Mawlawi; Jeremy J Erasmus; Reginald F Munden; Tinsu Pan; Amy E Knight; Homer A Macapinlac; Donald A Podoloff; Marvin Chasen
Journal:  AJR Am J Roentgenol       Date:  2006-02       Impact factor: 3.959

5.  Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer.

Authors:  Jeong-Yeol Park; Eyu Nyong Kim; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Gynecol Oncol       Date:  2008-01-16       Impact factor: 5.482

6.  Staging of uterine endometrial carcinoma with ultra-low field (0.02 T) MRI: a comparative study with CT.

Authors:  M J Varpula; P J Klemi
Journal:  J Comput Assist Tomogr       Date:  1993 Jul-Aug       Impact factor: 1.826

Review 7.  PET and PET-CT imaging of gynecological malignancies: present role and future promise.

Authors:  Sandip Basu; Geming Li; Abass Alavi
Journal:  Expert Rev Anticancer Ther       Date:  2009-01       Impact factor: 4.512

8.  Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability.

Authors:  Hedvig Hricak; Constantine Gatsonis; Fergus V Coakley; Bradley Snyder; Caroline Reinhold; Lawrence H Schwartz; Paula J Woodward; Harpreet K Pannu; Marco Amendola; Donald G Mitchell
Journal:  Radiology       Date:  2007-11       Impact factor: 11.105

9.  Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Chyong-Huey Lai; Kuan-Gen Huang; Lai-Chu See; Tzu-Chen Yen; Chien-Sheng Tsai; Ting-Chang Chang; Hung-Hsueh Chou; Koon-Kwan Ng; Swei Hsueh; Ji-Hong Hong
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

10.  Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer.

Authors:  Tzu-Chen Yen; Lai-Chu See; Chyong-Huey Lai; Chien-Sheng Tsai; Angel Chao; Swei Hsueh; Ji-Hong Hong; Ting-Chang Chang; Koon-Kwan Ng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-23       Impact factor: 10.057

View more
  12 in total

1.  NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system.

Authors:  Shuguang Chen; Yushen Gu; Haojun Yu; Xin Chen; Tuoyu Cao; Lingzhi Hu; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-03       Impact factor: 9.236

Review 2.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

3.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

Review 4.  Competitive advantage of PET/MRI.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Radiol       Date:  2013-06-18       Impact factor: 3.528

Review 5.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 6.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

Review 7.  PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer.

Authors:  Elizabeth A Sadowski; Ali Pirasteh; Alan B McMillan; Kathryn J Fowler; Joanna E Kusmirek
Journal:  Abdom Radiol (NY)       Date:  2021-10-23

Review 8.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

9.  Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tomonori Kanda; Tetsuo Maeda; Natsuko Makihara; Yasuhiko Ebina; Hideto Yamada; Satoru Takahashi; Kazuro Sugimura
Journal:  Ann Nucl Med       Date:  2013-10-16       Impact factor: 2.668

Review 10.  Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature.

Authors:  Alessandra Musto; Gaia Grassetto; Maria Cristina Marzola; Sotirios Chondrogiannis; Anna Margherita Maffione; Lucia Rampin; David Fuster; Francesco Giammarile; Patrick M Colletti; Domenico Rubello
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.